|
Cell>Point adds Dr. Eric
Kurzweil to Board of Advisors 9/11/2008
CENTENNIAL, Colo., September 11, 2008 Cell>Point is
pleased to announce that Eric Kurzweil, M.D., MBA has joined our Board
of Advisors. Dr. Kurzweil is currently President of the Rocky Mountain
Region of Pediatrix. Pediatrix, a $2.63 billion market cap company
listed on the NYSE:PDX which includes more than 900 physicians
nationwide. Dr. Kurzweil received his undergraduate degree from Harvard
University and his medical degree from the University of Miami School of
Medicine. Dr. Kurzweil earned his masters degree of business
administration from the University of Colorado.
Top
Cell>Point establishes European subsidiary 7|1|08
CENTENNIAL, Colo., July 1, 2008 - Cell>Point
announced today that it has established a subsidiary in the Netherlands,
Cell>Point Netherlands BV. Cell>Point plans to expand its operation in
Europe including financial partners and European clinical trial sites
for its Phase III clinical trials in 99mTc-EC-G.
Top
Cell>Point technology featured on Fox National News
4|18|08
CENTENNIAL, Colo., April 18, 2008 - Cell>Point announced today that EC
Technology was featured on Fox National News.
click here (video)
Top
Cell>Point featured on NBC 9 News 4|2|08
CENTENNIAL, Colo., April 2, 2008 - Cell>Point announced today that it
was featured on NBC 9 News Denver.
click here (video)
Top
Cell>Point to present at Wachovia 2008 Healthcare Conference 1|25|08
CENTENNIAL, Colo., January 25, 2008 Cell>Point, L.L.C. today announced
that it will present at the Wachovia 2008 Healthcare Conference, which
will be held January 29-31, 2008, at The Langham Hotel in Boston, Mass.
Cell>Point will present Thursday, January 31 at 1:00 pm (Eastern Time)
in the Palmer Room.
Top
Diagnostic Imaging April 2007 Article 4|18|07
Cell>Point was featured in the Diagnostic Imaging April 2007 issue
"Small biopharm company hatches plan to unseat FDG" according to Terry
Colip, Managing Partner of Cell>Point. To view article go to
www.diagnosticimaging.com April 2007 issue.
Top
Dr. F. David Rollo joins Cell>Point as President 9|12|06
CENTENNIAL, Colo., September 12, 2006 Terry Colip, Managing Partner
at Cell>Point today announced F. Dav ... full article
Top
Cell>Point featured on CNBC 9|7|06
CENTENNIAL, Colo., September 7, 2006 - Cell>Point will befeatured on
CNBC September 13, 2006. The video from CNBC will be available from our
homepage on September 22, 2006... full article
Top
Cell>Point expands clinical trial for Imaging Myocardial Viability
6|1|06
CENTENNIAL, Colo., June 1, 2006 -Cell>Point today announced it plans to
start a Phase II clinical trial to evaluate the effectiveness of its
99mTc-EC-DG (Technetium-99m-Ethylenedicys-teine-Deoxyglucose) in
diagnosing... full article
Top
Cell>Point named Biotech Rising Star of the Year 11|8|05
ENGLEWOOD, Colorado - November, 8, 2005 - Cell>Point was named Biotech
"Rising Star of the Year" by the Colorado BioScience Association
according to Terry Colip, Managing Partner of Cell>Point... full article
Top
Cell>Point acquires Oligosaccharide Conjugate License 6|3|05
HOUSTON, Texas - June 3, 2005 - Cell>Point obtained the worldwide patent
and technology license to Oligosaccharide Conjugates for Dual Imaging
and Radio/Chemotherapy developed at The University of Texas M. D.
Anderson Cancer Center. This novel technology is facilitating the
development of combination modality diagnostic imaging agents and new
combination radio/chemotherapeutic agents for use in oncology,
cardiology, neuroendocrinology and infectious diseases... full
article
Top
Cell>Point featured in Aunt Minnie 5|20|05
ENGLEWOOD,Colorado-May20,2005-Cell>Point was featured in the following
Aunt Minnie article
BiotechfirmCell>Point sees promise for oncology SPECT- By: Kate Madden
Yee ... full article
Top
EC Technology featured in Basel, Switzerland 4|21|05
HOUSTON, Texas - April 21, 2005 - Cell>Point announced today that David
J. Yang, Ph.D. will present our EC Technology at the Joint Meeting of
the Austrian, German, and Swiss Societies of Nuclear Medicine to be held
in Basel, Switzerland (April 27-30, 2005)... full article
Top
Cell>Point to present at 30th Annual Deutsche Bank Health Care
Conference 4|20|05
ENGLEWOOD, Colorado - April 20, 2005 -Cell>Point will be a presenting
company at the 30th Annual Deutsche Bank Health Care Conference to be
held in Baltimore, May 2-4, 2005. The webcast can be viewed at
http://www.corporate-ir.net/ireye/confRegistration.zhtml?ticker=W189917&item_id=ew,1055963,1,189917,438136,524157 ... full
article
Top
Cell>Point acquires N4 Technology License 3|1|05
HOUSTON, Texas - March 1, 2005 - Cell>Point obtained the worldwide
patent and technology license on February 14, 2005 to
tatraazacyclopentadecane (N4) technology developed at The University of
Texas M.D. Anderson Cancer Center. N4 Technology will form the
foundation for the development of Positron Emission Tomography imaging
agents using generator based isotopes as well as compounds for imaging
and treating neuroendocrine tumors and certain diseases affecting the
centra ... full article
Top
Cell>Point to Present at Rice Forum 2|22|05
HOUSTON, Texas - February 22, 2005 - Cell>Point has been selected to be
a presenting company at the 4th Annual Rice Alliance Life Science
Technology Venture Forum on March 11, 2005 at Rice University. Greg R.
Colip, President of the company, will present an overview of the company
and its technology platforms. The Rice Alliance Forum brings together
biotechnology companies, angel investors, venture capital firms and law
firms who specialize in the area of biotechnology. The Forum ... full
article
Top
Dr. Saad Zakko joins Scientific Advisory Board 9|8|04
HOUSTON, Texas - September 1, 2004 �Cell>Point is pleased to announce
that Dr. Saad Zakko has joined our Scientific Advisory Board. Dr. Zakko
has been Consultant to the Department of Nuclear Medicine at Dubai
Hospital
Top
Cell>Point completes clinical pilot study on 99mTc-EC-Annexin V 4|1|04
HOUSTON,Texas-April1,2004 -Cell>Point L.L.C. completes clinical pilot
study on 99mTc-EC-Annexin V at The University of Texas M.D. Anderson
Cancer Center. The study evaluated the use of 99m Tc-EC-Annexin V to
assess tumor apoptosis (programmed cell death) in patients with primary
breast cancer and to detect an ... full article
Top
Royal Philips Electronics collaborates with Cell>Point 9|29|03
HOUSTON, Texas - September 29, 2003 - Royal Philips Electronics (NYSE:
PHG, AEX: PHI) announced today that it will collaborate with Cell>Point,
L.L.C, a biotechnology company based in Englewood, Colo., to optimize
Cell>Point's novel diagnostic imaging agent on Philips' SKYLight า
gantry-free gamma camera. The companies will share clinical trial costs
to develop the best imaging techniques for improved clinical information
and accuracy of diagnoses. The joint goal is to develop ... full
article
Top
Cell>Point L.L.C. Completes Exclusive License Negotiations for Second
Technology Platform In Situ Hydrogel 7|1|03
In July 2003, the company completed exclusive license negotiations with
M.D. Anderson for a second technology platform, In Situ Hydrogel, which
will be used for local regional chemotherapy and radiotherapy. In
comparison with other hydrogel technologies, In Situ Hydrogel is the
only hydrogel formulation capable of delivering a high yield load of a
therapeutic radionuclide like 188Re directly to the tumor site without
leakage into surrounding tissue. The In Situ Hydrog ... full article
Top
Cell>Point L.L.C. Preparing to Conduct Studies 10|1|02
HOUSTON, Texas - October 2002 - Cell>Point L.L.C. is preparing to
commence clinical biokinetic and biodistribution studies at The
University of Texas M.D. Anderson Cancer Center on
99mTc-EC-Metronidazole, 99mTc-EC-Annexin V and 99mTc-EC-Cox-2. If
results from the studies are as expected, Cell>Point will prepare and
submit IND applications with the FDA for the three "kit" compounds... full article
Top
Cell>Point Receives Approval of its Investigations New Drug Application
for 99mTc-EC-Deoxyglucose 6|1|02
HOUSTON, Texas - June 2002 - Cell>Point L.L.C. (Englewood, CO) received
approval of its Investigational New Drug Application for
99mTc-EC-Deoxyglucose (known in the clinical trial as "CP6262") from the
FDA on June 26. The Phase I clinical trial will be conducted at The
University of Texas M.D. Anderson Cancer Center in Houston, Texas.
CP6262 is a technetium-99m labeled molecular imaging agent that will be
used as a diagnostic tool in oncology to identify active tumor ... full
article
Top
Cell>Point, L.L.C. Executes Exclusive Worldwide Patent and Technology
License Agreement for ethylenedicysteine 7|1|01
HOUSTON, Texas - July 2001 - Cell>Point, L.L.C. executed an exclusive
worldwide Patent and Technology License Agreement with The University of
Texas M.D. Anderson Cancer Center for ethylenedicysteine ("EC") drug
conjugate technology which functions as a chemical bridge linking
diagnostic radio-tracers or therapeutic radionuclides to ligand disease
target seekers or novel FDA approved drugs... full article
Top
|
